Chimerix (CMRX) Stock Price, News & Analysis

Company Overview

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Key Stats

• Today's Range: $8.54 to $8.54
• 50-Day Range: $8.54 to $8.54
• 52-Week Range: $0.75 to $8.55
• Volume: N/A
• Average Volume: 2.94 million shs
• Market Capitalization: $801.09 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 3/21/2025
• Today: 9/27/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:CMRX
• CIK: 1117480
• Web: www.chimerix.com
• Phone: (919) 806-1074
• Fax: 919-806-1146
• Employees: 90
• Year Founded: 2000

Profitability

• EPS (Trailing Twelve Months): ($0.99)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$82.10 million
• Net Margins: N/A
• Pretax Margin: -52,574.85%
• Return on Equity: -50.78%
• Return on Assets: -44.94%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.33
• Quick Ratio: 6.33

Sales & Book Value

• Annual Sales: $212 thousand
• Price / Sales: 3,778.71
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.17 per share
• Price / Book: 3.94

Miscellaneous

• Outstanding Shares: 93,804,000
• Free Float: 78,154,000
• Market Cap: $801.09 million
• Optionable: No Data
• Beta: -0.17